Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Mesothelioma, Malignant 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Solid Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Metastatic Solid Tumors 1Metastatic NUT Carcinoma 1Melanoma 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cervical Adenocarcinoma 1Carcinoma, Small Cell 1Carcinoma, Neuroendocrine 1Bone Neoplasms 1Advanced NUT Carcinoma 1

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic NUT Carcinoma × Platinum × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡